FDA Approves Roche Drug for Advanced Breast Cancer
The FDA approved Roche’s oral drug Wilserdly (giredestrant) with everolimus for adults with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer who have relapsed or progressed after hormone-based treatment. In the phase III evERA trial, the combination reduced the risk of disease progression or death by 62% and delayed progression for a median of 10 months, compared with 5.5 months for another hormone treatment plus everolimus. Because ESR1 mutations can contribute to resistance to hormone therapy, the FDA also authorized a blood test to identify eligible patients. Roche says the drug could become its top seller; the FDA is separately reviewing it for use after surgery, with a decision expected by Nov. 30, 2026.







